Table 1.
Baseline characteristics by genetic subgroups
| Baseline Characteristics | All patients (n=257) |
Genetic subgroup
|
P-value† | ||
|---|---|---|---|---|---|
| No variants (n=133) |
1 variant (n=75) |
≥2 variants (n=49) |
|||
| Age (years), mean ± SD | 51 ± 16 | 51 ± 15 | 50 ± 17 | 53 ± 16 | 0.61 |
|
| |||||
| Female sex, % | 49.4 | 49.6 | 48.0 | 51.0 | 0.95 |
|
| |||||
| BSA (m2), mean ± SD | 2.1 ± 0.4 | 2.1 ± 0.4 | 2.0 ± 0.4 | 2.0 ± 0.3 | 0.22 |
|
| |||||
| Baseline INR, mean ± SD | 1.2 ± 0.1 | 1.2 ± 0.1 | 1.2 ± 0.2 | 1.2 ± 0.1 | 0.95 |
|
| |||||
| Self-reported race/ethnicity, % | |||||
| African American | 55.3 | 77.4 | 38.7 | 20.4 | <0.0001 |
| Non-Hispanic Caucasian | 15.6 | 8.3 | 20.0 | 28.6 | |
| Hispanic Caucasian | 17.1 | 6.8 | 28.0 | 28.6 | |
| Asian | 2.3 | 0.8 | 1.3 | 8.2 | |
| Other | 9.7 | 6.8 | 12.0 | 14.3 | |
|
| |||||
| Warfarin indication, % | |||||
| VTE | 62.3 | 66.9 | 57.3 | 57.1 | 0.28 |
| Atrial fibrillation | 19.1 | 16.5 | 22.7 | 20.4 | 0.54 |
| Atrial or ventricular thrombus | 4.3 | 5.3 | 2.7 | 4.1 | 0.72 |
| Cardioembolic stroke | 3.5 | 2.3 | 6.7 | 2.0 | 0.22 |
| Cerebral venous thrombosis | 3.5 | 3.0 | 1.3 | 8.2 | 0.15 |
| Other* | 7.4 | 6.0 | 9.3 | 8.2 | 0.63 |
|
| |||||
| Setting of first therapeutic INR (n=173) | |||||
| Inpatient, % | 60.7 | 65.1 | 52.8 | 62.2 | 0.36 |
| Outpatient, % | 39.3 | 34.9 | 47.2 | 37.8 | |
INR – international normalized ratio; SD – standard deviation; VTE – venous thromboembolism
†
P-values were generated from χ2 test of independence or analysis of variance (ANOVA) in order to assess differences among the 3 genetic subgroups (i.e. 0, 1, or ≥2 reduced-function alleles)
*
Arterial dissection, splenic vein thrombosis, antiphospholipid antibody syndrome, heart failure, pulmonary hypertension, arteriovenous fistula thrombus, inferior vena cava thrombus, portal vein thrombosis, peripheral vascular disease graft, heel ulcer, renal vein thrombosis, right internal jugular thrombosis